Antiepileptic drugs in schizophrenia: A review

European Psychiatry

Volumn 17, Issue 7, 2002, Pages 371-378

  Hosak L ^a,b   Libiger, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Antiepileptic drugs; Gamma aminobutyric acid; Glutamate; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANXIETY; BEHAVIOR; DISEASE RESISTANCE; DRUG MECHANISM; GABAERGIC SYSTEM; HISTORY OF MEDICINE; HOSTILITY; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; PUBLISHING; REVIEW; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 0036859330     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(02)00696-X     Document Type: Review

References (43)

1. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatr 2000;57:270-6.
2. Brewerton TD. The phenomenology of psychosis associated with complex partial seizure disorder. Ann Clin Psychiatr 1997;9:31-51.
3. Citrome L, Levine J, Allingham B. Utilization of valproate: Extent of inpatient use in the New York state office of mental health. Psychiatr Quarterly 1998;69:283-300.
4. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatr 1991;148:1474-86.
5. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000;20(Suppl 1):1S-17S.
6. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12:1-13.
7. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998;31:122-5.
8. Dursun SM, McIntosh D. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatr 1999;56:950.
9. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: A possible interaction. J Toxicol Clin Toxicol 1998;36:195-203.
10. Facciola G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monitoring 1999;21:341-5.
11. Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 1995;36(Suppl 2):S105-114.
12. Galletly CA, Tsourtos G. Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Ann Clin Psychiatr 1997;9:77-80.
13. Gündürewa M, Beckmann H, Zimmer R, Rüther E. Wirkung von valproinsäure auf schizophrene syndrome. Arzneim Forsch 1980;30:1212-3.
14. Gutiérrez K, Walter H, Bankier B. Valproic acid and carbamazepine: A successful antipsychotic medication? The problem of diagnosis and its relevance for therapy. Psychopathology 1999;32:235-41.
15. Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J. Zur adjuvanten behandlung schizophrener störungen mit carbamazepin. Fortschr Neurol Psychiat 1998;66:145-50.
16. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993;13(Suppl 1):72S-81S.
17. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28.
18. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988;1(8585):583-4.
19. Kim JS, Kornhuber HH, Holzmüller B, Schmid-Burgk W, Mergner T, Krzepinski G. Reduction of cerebrospinal fluid glutamic acid in huntington's chorea and in schizophrenic patients. Arch Psych Nervenkrankheiten 1980;228:7-10.
20. Koran LM. Gamma-aminobutyric-acid deficiency in schizophrenia. Lancet 1976;2(7993):1025.
21. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatr 1994;51:199-214.
22. Lewohl JM, Crane DI, Dodd PR. Zolpidem binding sites on the GABA(A) receptor in brain from human cirrhotic and non-cirrhotic alcoholics. Eur J Pharmacol 1997;326:265-72.
23. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(Suppl 2):S2-12.
24. Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatr 1996;8:89-91.
25. Meltzer HY, Goode DJ, Fang VS, Schyve P, Young M. Dopamine and schizophrenia. Lancet 1976;2(7995):1142.
26. Messenheimer JA. Lamotrigine. Epilepsia 1995;36(Suppl 2):S87-94.
27. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998;18:281-96.
28. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hill J Clin Psychiatr 1989;11:199-207.
29. Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatr 1994;35:22-6.
30. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatr 1993;54(Suppl 9):42-9.
31. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-9.
32. Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatr 1994;55(Suppl B):43-6.
33. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatr 1995;52:998-1007.
34. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991;254:1515-8.
35. Post RM. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr Res 1999;39:153-8.
36. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatr 2000;47:22-8.
37. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review. J Psychiatr Neurosci 1992;17:1-14.
38. Simhandl C, Meszaros K, Denk E, Thau K, Topitz A. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia. Can J Psychiatr 1996;41:317.
39. Siow-Ann C, Chay-Hoon T, Ee-Lian L, Pei-Hsiang L. Augmentation of risperidone with valproic acid. J Clin Psychiatr 1998;59:430.
40. Smith ME. A clinical study of chlorpromazine and chlordiazepoxide. Conn Med 1961;25:153-7.
41. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999;19:222-32.
42. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: A three-case report. J Clin Psychopharmacol 1989;9:45-8.
43. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatr 1991;148:714-26.